Back to Trades
Total Value
$NaN
Filing Date
Aug 19, 2025
1 transactions
Trade Summary
On Jun 20, 2025, Simcere Zaiming, Inc., 10% Owner, reported $NaN of NextCure, Inc. (NXTC) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- NextCure, Inc.
- Ticker Symbol
- NXTC
- CIK
- 0001661059
Insider Information
- Role
- 10% Owner
- Location
- CAMBRIDGE, MA
Filing Details
- Filing Date
- Aug 19, 2025
- Transaction Date
- Jun 20, 2025
- Accession Number
- 0001213900-25-078673
- Form Type
- 3
Want live alerts when Simcere Zaiming, Inc. trades again?
Download Insider Trades to track NXTC, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)These securities are directly held by Simcere Zaiming, Inc. ("Simcere Zaiming" or the "Reporting Person") and may be deemed to be indirectly beneficially owned by the other persons.
- (F2)Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming, Inc. Hainan Simcere Zaiming Pharmaceutical Co., Ltd. ("Hainan Zaiming") is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Hainan Zaiming through several intermediate companies. Mr. Ren Jinsheng is the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming. Mr. Tang Renhong is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren Jinsheng and Tang Renhong may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described in this footnote.
- (F3)The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that the Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.